* Pharvaris NV PHVS.OQ PHVS.O is expected to show no
change in
quarterly revenue when it reports results on May 9
(estimated).
*
* Refinitiv's mean analyst estimate for Pharvaris NV is for
a
loss of 74 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pharvaris
NV is
$18, above its last closing price of $9.03.
Previous quarterly performance (using preferred earnings measure
in euros).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.68 -0.65 -1.17 Missed -79.4
Sep. 30 2022 -0.63 -0.63 -0.25 Beat 60.5
Jun. 30 2022 -0.57 -0.56 -0.38 Beat 31.8
Mar. 31 2022 -0.43 -0.49 -0.48 Beat 2.7
Dec. -0.99 -0.71 -0.09 Beat 87.3
31 2021
Sep. 30 2021 -0.44 -0.42 -0.39 Beat 7.1
Jun. 30 2021 -0.39 -0.39 -0.94 Missed -141
Mar. 31 2021 -0.34 -0.34 -0.66 Missed -95.6
This summary was machine generated May 5 at 13:42 GMT. All
figures in euros unless otherwise stated